Company Overview

Nyrada is a drug discovery and development company focused on innovative Transient Receptor Potential Canonical (TRPC) ion channel blockers.  We are listed on the Australian Securities Exchange (ASX) under the ticker ASX:NYR.

Nyrada’s vision is to become a high growth pharmaceutical company specialising in drug discovery and early-stage drug development. Our drug development programs focus on areas of substantial unmet clinical need where few if any, effective or well-tolerated therapies exist.

Nyrada is developing NYR-BI03, a first-in-class neuroprotection and cardioprotection treatment.

In February 2024, Nyrada announced preclinical stroke study results showing that NYR-BI03 achieved a statistically significant neuroprotective effect, rescuing 42% of brain tissue in the penumbra region of treated animals.

In October 2024, Nyrada announced the results of a preclinical coronary heart disease study which showed that NYR-BI03 provided an 86% cardioprotective effect following myocardial ischemic-reperfusion injury, a leading cause of tissue damage when blood flow is restored to the heart after injury.

In March 2025, Nyrada commenced its first-in-human Phase Ia clinical trial to assess the safety, tolerability, and pharmacokinetics of NYR-BI03 in healthy human volunteers.